Bevacizumab for the second line treatment of HER2 negative metastatic breast cancer
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2011
Topic area
  • Cancer

Scoped within Batch 19

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
7 November 2011

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of bevacizumab in combination with chemotherapy for the second line treatment of human epidermal growth factor 2 (HER2) negative metastatic breast cancer as part of our 27th work programme.

The Institute has now been informed by the manufacturer that it has decided not to apply for a centralised marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual